Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing

Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC

  Aadi Enters Agreement to Sell FYARRO^® and Associated Infrastructure to KAKEN Pharmaceutical for $100M; Announces PIPE Financing of $100M

Read more at prnewswire.com